Vaccine
Prestige®
with Havlogen®
Indications

For vaccination of healthy horses 6 months of age or older, as an aid in the control of respiratory disease and as an aid in the reduction of virus shedding caused by Equine herpesvirus type 1 (EHV-1) and equine herpesvirus type 4 (EHV-4).

The Science of Protected

  • EHV-1 and EHV-4, or rhino, can cause respiratory tract infections. EHV 4 is typically associated with upper respiratory disease in younger horses. EHV-1 can cause respiratory disease, late-term abortions, early foal deaths, neurologic disease
  • A combination of inactivated, purified, concentrated, adjuvanted, equine tissue culture origin equine herpesviruses types 1 and 4 (EHV-1 and EHV-4).
  • Exceptional safety profile with the smooth Havlogen® adjuvant
  • Advanced filtration process through the Antigen Purification System (APS)

Science

Resources

Administration

Dose:

For primary vaccination aseptically administer 1 mL intramuscularly, repeat with a single dose in 4-6 weeks. Annual revaccination is recommended. A booster dose can be administered at more frequent intervals based upon individual horse or farm disease risk assessment or any time epidemic conditions exist or are reported. Consult your veterinarian.